Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Med.

Sec. Family Medicine and Primary Care

Volume 12 - 2025 | doi: 10.3389/fmed.2025.1638127

This article is part of the Research TopicThe Increasing Relevance of Traditional Medicine Systems for the Primary Health Care Sector and General Practice: Global Research Perspectives – Volume IIView all 30 articles

ESTIMATION OF INFLAMMATORY BIOMARKER IL-6 IN BLOOD SAMPLES OF VARICOSE VEINS AFTER REPEATED SIRĀVYADHA''(Venesection/Bloodletting)

Provisionally accepted
  • 1Amrita School of Ayurveda, Kollam, India
  • 2amrita vishwa vidhyapeetham amrita school of ayurveda, kollam, India

The final, formatted version of the article will be published soon.

Introduction: Sirāgranthi results from vitiated vāta in sirās, leading to granthi due to Vātaprakopaka nidānas. Ācārya Vagbhata recommends sirāvyadha for treating sirāgranthi. The role of inflammation in vascular diseases is explored, with a focus on Interleukin-6 as a key biomarker. The absence of studies on sirāvyadha's impact on inflammatory biomarkers, particularly Interleukin-6, underscores the study's relevance, aiming to observe changes in inflammatory response in varicose veins post-sirāvyadha within a 15-day period. Objective: To observe changes in IL-6 values before and after sirāvyadha within a 15-day period in individuals with varicose veins. Materials and Methods: After excluding deep vein thrombosis (DVT) through lower limb color doppler, five subjects who satisfied the inclusion criteria were selected. Assessments included BT, CT, Hb screening, and parameters like AVVQ, pain, edema, tortuosity, skin pigmentation, and itching. Sirāvyadha was performed over the tortuous vein with an 18G needle, and sample was collected from drained blood for IL-6 testing. After a 15-day follow-up, Sirāvyadha was repeated, and assessment of all parameters were done. Results: Statistically significant differences (p<0.05) were observed after treatment in Interleukin-6, AVVQ, pain, edema, tortuosity, and skin pigmentation. However, itching showed no statistically significant difference after treatment (p>0.05). Conclusion: In all 5 cases, a reduction in the rate of IL-6 was observed. Remarkably, three patients with initially high values showed a statistically significant reduction (p<0.05) after sirāvyadha treatment, indicating a reduction in inflammation. Clinical and statistical significance (p<0.05) were also observed in subjective parameters such as pain, edema, tortuosity, and skin pigmentation. Although itching decreased in patients, it did not reach statistical significance, possibly due to some patients not experiencing itching before the procedure. The study demonstrates that sirāvyadha effectively reduces the inflammatory response and subjective symptoms of varicose veins. Furthermore, the improvement in the quality of life after sirāvyadha was highly significant (p<0.05). Overall, the study supports sirāvyadha's efficacy in reducing inflammatory biomarker IL-6 and subjective symptoms in varicose veins.

Keywords: Varicose Veins, Interleukin 6 (Il 6), siragranthi, siravyadha, venesec, Blood letting therapy, quality of life

Received: 30 May 2025; Accepted: 13 Oct 2025.

Copyright: © 2025 Sivadas, I.V., U and Namboothiri. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: K.Parameswaran Namboothiri, nambu24@gmail.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.